Robert Carlson, MD
NCCN Guidelines for Chronic Myelogenous Leukemia and Multiple Myeloma will be the first to incorporate cost elements.
The NCCN also plans to incorporate cost into the existing NCCN Chemotherapy Order Templates.
The payer Anthem says drug valuation tools fall short of need, but are an “extremely positive step.”
ASCO’s drug valuation tool will supplement the CancerLinQ patient information portal to more broadly inform treatment decisions.
As cancer drugs soar in price, the National Comprehensive Cancer Network (NCCN) is introducing cost as a measure of the overall value of a therapy, following the trail of ASCO and a doctor from Memorial Sloan Kettering Cancer Center in attempting to put a lid on drug inflation.
... to read the full story